ATE25690T1 - Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems. - Google Patents

Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems.

Info

Publication number
ATE25690T1
ATE25690T1 AT83111816T AT83111816T ATE25690T1 AT E25690 T1 ATE25690 T1 AT E25690T1 AT 83111816 T AT83111816 T AT 83111816T AT 83111816 T AT83111816 T AT 83111816T AT E25690 T1 ATE25690 T1 AT E25690T1
Authority
AT
Austria
Prior art keywords
solution
disorders
treatment
coagagation
active
Prior art date
Application number
AT83111816T
Other languages
German (de)
English (en)
Inventor
Wolfgang Dr Dipl-Chem Stephan
Ronald Dr Dipl-Chem Kotitschke
Original Assignee
Biotest Serum Institut Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotest Serum Institut Gmbh filed Critical Biotest Serum Institut Gmbh
Application granted granted Critical
Publication of ATE25690T1 publication Critical patent/ATE25690T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8128—Antithrombin III
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT83111816T 1982-12-21 1983-11-25 Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems. ATE25690T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19823247150 DE3247150A1 (de) 1982-12-21 1982-12-21 Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems
EP83111816A EP0111777B1 (de) 1982-12-21 1983-11-25 Gerinnungsaktive Plasmaproteinlösung, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Störungen des Hämostasesystems

Publications (1)

Publication Number Publication Date
ATE25690T1 true ATE25690T1 (de) 1987-03-15

Family

ID=6181202

Family Applications (1)

Application Number Title Priority Date Filing Date
AT83111816T ATE25690T1 (de) 1982-12-21 1983-11-25 Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems.

Country Status (5)

Country Link
US (1) US4503039A (US06811534-20041102-M00003.png)
EP (1) EP0111777B1 (US06811534-20041102-M00003.png)
JP (1) JPS59118710A (US06811534-20041102-M00003.png)
AT (1) ATE25690T1 (US06811534-20041102-M00003.png)
DE (2) DE3247150A1 (US06811534-20041102-M00003.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0212040B1 (de) * 1985-08-05 1990-05-23 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren
JPS6317899A (ja) * 1986-07-09 1988-01-25 Green Cross Corp:The ハプトグロビンの精製方法
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
JPH0219400A (ja) * 1988-07-07 1990-01-23 Green Cross Corp:The トロンビンまたはプロトロンビンの製造方法
US7211380B1 (en) * 1989-03-01 2007-05-01 Shionogi & Co., Ltd. Physiologically active polypeptide and DNA
US6187572B1 (en) 1990-04-16 2001-02-13 Baxter International Inc. Method of inactivation of viral and bacterial blood contaminants
US5418130A (en) * 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
US5520885A (en) * 1993-01-19 1996-05-28 Thermogenesis Corporation Fibrinogen processing apparatus, method and container
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
CA2460023A1 (en) * 2001-09-10 2003-03-20 Zymogenetics, Inc. Method for treating coumarin-induced hemorrhage
EP1935429A1 (en) 2006-12-22 2008-06-25 CSL Behring GmbH Synergistic therapeutic use of prothrombin complex concentrates with FVIII concentrates
WO2011150284A2 (en) 2010-05-26 2011-12-01 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EP3694322B1 (en) 2017-10-09 2024-07-03 Terumo BCT Biotechnologies, LLC Lyophilization container and method of using same
WO2020185916A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization container fill fixture, system and method of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6702923A (US06811534-20041102-M00003.png) * 1966-04-06 1967-10-09
DE2459291C3 (de) * 1974-12-14 1981-06-04 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung eines antihämophiles Globulin A enthaltenden Konzentrats neben einem Prothrombin- Komplex und einer Lösung von lagerstabilen Serumproteinen
US3998946A (en) * 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2902158A1 (de) * 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen

Also Published As

Publication number Publication date
JPH0425255B2 (US06811534-20041102-M00003.png) 1992-04-30
DE3247150A1 (de) 1984-06-28
DE3369998D1 (en) 1987-04-09
EP0111777A1 (de) 1984-06-27
EP0111777B1 (de) 1987-03-04
JPS59118710A (ja) 1984-07-09
US4503039A (en) 1985-03-05

Similar Documents

Publication Publication Date Title
ATE25690T1 (de) Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems.
EP0784632B1 (de) Verfahren zur gewinnung von hochreinem von willebrand-faktor
Ratnoff et al. The activation of Christmas factor (factor IX) by activated plasma thromboplastin antecedent (activated factor XI)
US4789545A (en) Removal of lipid soluble process chemicals from biological materials by extraction with naturally occurring oils or synthetic substitutes thereof
US3686395A (en) Process for preparation of storage stable hepatitis-free serum
US9034646B2 (en) Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof
AU6567086A (en) Compositions and methods for the treatment of bleeding disorders
PH23248A (en) Process for the preparation of quinolone-carboxylic acid
US4465623A (en) Prothrombin complex concentrates, preparation and application thereof
EP0774261A2 (de) Verwendung von von Willebrand-Faktor und pharmazeutische Zubereitung
CA2068069C (en) Blood coagulation factor xi concentrate having high specific activity, suitable for therapeutic use, and process for preparing same
PL82807B1 (US06811534-20041102-M00003.png)
Weissberg et al. Effects of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin upon hemostasis and hematologic function in the rat.
US4822872A (en) Method of purifying factor VIII
AU2381795A (en) Methods for treating bleeding disorders
CN106928344A (zh) 用于从含有凝血因子的溶液中减少和/或除去FXI和FXIa的方法
US2175090A (en) Purification of antibody compositions
US3905870A (en) Purification of kallikrein
JPS57150382A (en) Purification of super oxide dismutase
MORIYA et al. Biochemical Studies on Kallikreins and Their Related Substances III. Preliminary Experiment of Studies on Human Plasma Kallikrein
JPS6237009B2 (US06811534-20041102-M00003.png)
Sutor et al. Haemostatic Deterioriation after Therapy with Plasma and Plasma Derivatives
JPH0725696B2 (ja) プラスミノ−ゲンの安定化方法
JPH01315337A (ja) 脂質用吸着剤の使用方法
JPS5649394A (en) Preparation of blood coagulation factor 5, and determination of abnormal prothrombinase activity